Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 12/20 | 0.84 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18105516 | 0.91 | SLC22A12 (1.00) | SLC22A12 | |
| SCHEMBL19456910 | 0.89 | SLC22A12 (0.79) | SLC22A12KDM1AEGLN2GAA | |
| SCHEMBL18105594 | 0.86 | SLC22A12 (0.75) | SLC22A12KDM1AEGLN2GAA | |
| SCHEMBL19967246 | 0.77 | SLC22A12 (0.62) | SLC22A12KDM1AEGLN2GAAGRIA1 | |
| SCHEMBL19456815 | 0.72 | SLC22A12 (0.69) | SLC22A12 | |
| SCHEMBL19456909 | 0.72 | SLC22A12 (0.67) | SLC22A12 | |
| SCHEMBL18105513 | 0.71 | SLC22A12 (0.54) | SLC22A12KDM1AEGLN2GRIA1 | |
| SCHEMBL19456744 | 0.70 | SLC22A12 (0.62) | SLC22A12 | |
| SCHEMBL21727938 | 0.70 | SLC22A12 (0.82) | SLC22A12 | |
| SCHEMBL19456820 | 0.70 | SLC22A12 (0.53) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | URB2, UGP2, NLRP3 | SLC22A12 578/4885KDM1A 1974/4885EGLN2 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.